CargoAdmin, Bureaucrats, Moderators (CommentStreams), fileuploaders, Interface administrators, newuser, Push subscription managers, Suppressors, Administrators
14,662
edits
Novartis: Difference between revisions
m
Text replacement - "The Wall Street Journal" to "The Wall Street Journal"
m (1 revision imported) |
m (Text replacement - "The Wall Street Journal" to "The Wall Street Journal") |
||
| Line 509: | Line 509: | ||
|Stalevo ([[carbidopa]]/[[levodopa]]/[[entacapone]])||Parkinson's disease|| || || || | |Stalevo ([[carbidopa]]/[[levodopa]]/[[entacapone]])||Parkinson's disease|| || || || | ||
|- | |- | ||
|Tasigna ([[nilotinib]])||Chronic myelogenous leukemia (first-line treatment<ref name="wsjtasigna2012">{{Citation |title=NICE Backs Novartis's Tasigna For CML, Rejects BMS's Sprycel |date=12 January 2012 |url=https://online.wsj.com/article/BT-CO-20120112-715529.html |work= | |Tasigna ([[nilotinib]])||Chronic myelogenous leukemia (first-line treatment<ref name="wsjtasigna2012">{{Citation |title=NICE Backs Novartis's Tasigna For CML, Rejects BMS's Sprycel |date=12 January 2012 |url=https://online.wsj.com/article/BT-CO-20120112-715529.html |work=The Wall Street Journal |df=dmy |archive-url=https://web.archive.org/web/20130517062555/http://online.wsj.com/article/BT-CO-20120112-715529.html |at=online.wsj.com |access-date=2012-01-15 |archive-date=17 May 2013 |url-status=dead}}</ref>)||998 ||2012<ref name=2012Sales/> ||39% ||[[NICE]] formulary approval, January 2012<ref name=wsjtasigna2012/> | ||
|- | |- | ||
|Tegretol ([[carbamazepine]])||[[Epilepsy]], [[bipolar disorder]]||413||2007<ref name=novartis2007sales/>||6% || | |Tegretol ([[carbamazepine]])||[[Epilepsy]], [[bipolar disorder]]||413||2007<ref name=novartis2007sales/>||6% || | ||